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Abstract  
Acute inflammation is a protective response of the body to harmful 
stimuli, such as pathogens or damaged cells. However, dysregulated 
inflammation can cause secondary damage and could thus contribute to the 
pathophysiology of many diseases. Inflammasomes, the macromolecular 
complexes responsible for caspase-1 activation, have emerged as key 
regulators of immune and inflammatory responses. Therefore, modulation of 
inflammasome activity has become an important therapeutic approach. Here we 
describe the design of a smart nanodevice that takes advantage of the passive 
targeting of nanoparticles to macrophages and enhances the therapeutic effect 
of caspase-1 inhibitor VX-765 in vivo. The functional hybrid systems consisted 
of MCM-41-based nanoparticles loaded with anti-inflammatory drug VX-765 
(S2-P) and capped with poly-L-lysine, which acts as a molecular gate. S2-P 
activity has been evaluated in cellular and in vivo models of inflammation. The 
results indicated the potential advantage of using nanodevices to treat 
inflammatory diseases. 
Keywords  
Gated mesoporous silica nanoparticles, controlled release, inflammasome, VX-
765, macrophages, air pouch mouse model.  
 
1. Introduction 
The use of gated materials in biomedical applications has increased in the 
past few years thanks to their ability to release therapeutic drugs upon the 
application of external stimuli. These nanodevices have attracted much attention 
as candidates for the development of potential new therapies to improve drug 
efficacy and safety, and are potential alternatives to liposomes and polymeric 
carriers, which usually release their cargo via simple diffusion-controlled 
processes or through container degradation [1-7]. Gated nanoparticles have 
been used for controlled delivery applications since the first report by Fujiwara 
and co-workers [8, 9]. To date, several examples of gated systems capable of 
delivering their cargo have been described [10] upon the application of specific 
chemical [11-14] physical [15-17] and biochemical [18-20] stimuli.  
The unique properties of mesoporous silica nanoparticles (MSNs), such as 
large loading capacity, low toxicity, stability, biocompatibility and easy 
functionalization, make them most appealing as carriers for drug storage and 
on-command delivery [21-23]. Moreover, gated MSNs are also suitable 
nanocarriers of poor soluble drugs and are able to protect drugs from 
degradation [24-27]. The combination of the remarkable properties of MSNs as 
nanocarriers and the use of polymers as caps has been proven a feasible 
procedure to develop drug delivery systems for applications in a more biological 
and realistic environment. In this subfield of research, several examples have 
been reported in the literature on MSNs with polymers capable of delivering the 
payload by changes in temperature, pH, redox activity and by presence of 
target enzymes [10] [28].  
From another point of view, the intrinsic capacity of macrophages to 
internalize foreign bodies evidences their potential use for targeting drug 
delivery using nanoparticles [29-31]. Accordingly, efforts made to develop 
innovative therapies have been reported that use nanomaterials as 
intramacrophagic vectors to enhance the antimicrobial effects of antibiotics, 
based mainly on liposomes [32, 33], polymeric [34, 35] and carbon nanotube 
[36, 37] carriers. While the use of liposomes, solid lipid particles and 
biodegradable nanoparticles has been described to target macrophages and 
deal with infectious diseases, the use of gated silica nanoparticles as a delivery 
platform to manage inflammation by taking advantage of targeting passive for 
macrophages has not been previously reported. Very few recent reports have 
been found that describe the use of MSNs in the inflammation field that lead to 
infectious diseases [38] and neuroinflammation [39].  
Macrophages are cells implicated in host defense that attack harmful 
substances through destruction and ingestion associated with an inflammatory 
response to limit harm to the body [40]. Dysregulated macrophage function and, 
thus dysregulated inflammation, have been implicated in the pathophysiology of 
a wide range of disorders, including chronic ulcers, allergic asthma, 
atherosclerosis, autoimmune disorders and fibrotic diseases, Alzheimer’s 
disease, etc. [41]. Inflammation initiates upon the sensing of signs of acute 
damage or disturbances in tissue homeostasis, which results in the synthesis 
and activation of potent pro-inflammatory cytokines, such as pro-Interleukin-1 
beta (pro-IL-1β) [42]. This activation is a proteolytic process controlled by 
interleukin-1 beta (IL-1β)-converting enzyme, caspase-1, which cleaves key 
pro-inflammatory cytokine IL-1β to trigger inflammation [43]. The protein 
complexes responsible for caspase-1 activation are inflammasomes [44]. 
Inflammasomes are molecular platforms formed by an inflammasome sensor 
molecule (the NLR protein), adaptor protein ASC and protease caspase-1. The 
formation of these multiprotein oligomers activates caspase-1 that triggers the 
maturation of pro-inflammatory cytokines IL-1β and IL-18 [45]. Another 
consequence of caspase-1 activation in macrophages is a pro-inflammatory 
form of caspase-1-dependent cell death, known as pyroptosis [46, 47]. 
Alterations in inflammasome components are involved in the physiopathology of 
several of the above-mentioned inflammatory diseases [48]. Therefore, 
modulation of inflammasome activity is an important target to develop effective 
therapeutics to treat inflammation and related inflammatory diseases.  
One emerging strategy to treat inflammatory diseases consists of drugs 
that target caspase activity. One specific inhibitor of caspase-1 is VX-765, a 
prodrug converted efficiently into the potent and selective inhibitor of 
ICE/caspase-1 VRT-043198 with the action of esterases. The therapeutic effect 
of this drug has already been demonstrated in preclinical studies and clinical 
trials to treat inflammatory and autoimmune conditions. Former studies have 
shown their therapeutic potential effect by reducing disease severity and 
inflammatory response in mouse models of rheumatoid arthritis and skin 
inflammation. Reducing cytokines production by inhibiting caspase-1, using 
drugs like VX-765, is a promising approach to consider the important role of 
these cytokines in inflammatory diseases [49, 50].  
Here we report the synthesis, characterization and controlled release 
behavior of gated-MSNs in both in vitro and in vivo models of inflammation. 
MSNs nanodevices were loaded with rhodamine B (S1) or drug VX-765 (S2), 
and were capped with polymer ε-poly-L-lysine. Nanoparticles showed “zero 
release”, yet cargo was delivered in the presence of a target stimulus (presence 
of pronase enzymes). Nanoparticles’ behavior was studied in the THP-1 acute 
monocytic leukemia cell line stimulated, or not, with lipopolysaccharide (LPS) 
and muramyl dipeptide (MDP) to produce the synthesis of pro-IL1-β and the 
activation of pro-caspase-1 by the inflammasome. Capped nanoparticles were 
also evaluated in a subcutaneous air pouch inflammation mouse model. 
2. Materials and methods  
2.1. General methods.  
Powder X-ray diffraction (PXRD), thermogravimetric analysis (TGA), 
transmission electron microscopy (TEM), N2 adsorption-desorption and 
elemental analyses were run to characterize synthesized materials. PXRD 
measurements were taken with a Philips D8 Advance Diffractometer using 
CuKα radiation. TGAs were carried out on a TGA/SDTA 851e Mettler Toledo 
balance in an oxidant atmosphere (air, 80 mL/min) with a heating program that 
consisted of a heating ramp of 10°C per minute from 25ºC to 100ºC. Then the 
temperature was kept at 100ºC for 60 min. Finally, a new heating ramp of 10ºC 
per minute from 100ºC to 1000ºC was applied and an isothermal heating step at 
the final temperature for 30 min. TEM images were obtained under a 100 KV 
JEM-1010 microscope. N2 adsorption-desorption isotherms were recorded with 
a Micromeritics ASAP2010 automated sorption analyzer. Samples were 
degassed at 120°C in vacuum overnight. Specific surface areas were calculated 
from the adsorption data within the low pressure range using the BET model. 
Pore size was determined following the BJH method. To determine the zeta 
potential of the bare and functionalised MSPs, a Zetasizer Nano ZS equipment 
(Malvern Instruments, Malvern, UK) was used. Samples were dispersed in 
distilled water at a concentration of 1 mg/mL. Before each measurement, 
samples were sonicated for 2 min to preclude aggregation. The zeta potential 
was calculated from the particle mobility values by applying the Smoluchowski 
model. The average of five recordings was reported as zeta potential. The 
measurements were performed at 25ºC and performed in triplicate. Dynamic 
light scattering (DLS) studies for the determination of particle size were 
conducted at 25ºC in a Malvern Zetasizer Nano ZS instrument; all the 
measurements were taken in triplicate on previously sonicated highly dilute 
water dispersions. Fluorescence spectroscopy was carried out with a JASCO 
spectrofluorometer FP-8300. HPLC analyses were performed with a Merck 
Hitachi L-2130 HPLC pump and an L-2200 autosampler using a Lichrospher® 
100 C18 (150 x 3.9 mm) column, and different acetonitrile gradients in aqueous 
0.1 % TFA as the mobile phase. Live cellular internalization studies were 
carried out with a Cytomics FC 500 (Beckman Coulter, Inc.). Cell viability and 
fluorescence spectroscopy measurements were taken with a Wallac 1420 
workstation. Silicon determination in mice was made by ICP-MS 7900 from 
Agilent. 
2.2. Chemicals.  
Chemicals tetraethylorthosilicate (TEOS), n-cetyltrimethylammonium 
bromide (CTABr), sodium hydroxide, (3-isocyanatopropyl)triethoxysilane, 
rhodamine B, trimethylamine, dimethyl sulfoxide (DMSO) and the pronase 
enzyme from Streptomyces griseus were purchased from Sigma Aldrich 
Química (Madrid, Spain). VX-765 was provided by AdooQ Bioscience. ε-Poly-L-
lysine was purchased from Chengdu Jinkai Biology Engineering CO., Ltd. All 
the other reagents were of a general laboratory grade and were purchased from 
Merck, unless otherwise stated. For the cell biology studies, RPMI-1640, fetal 
bovine serum (FBS), Dulbecco’s phosphate-buffered saline (PBS), 
lipopolysaccharides (LPS) from Escherichia coli 055:B55 (in vitro experiments), 
0111:B4 (in vivo experiments), adenosine 5’- triphosphate disodium salt (ATP), 
N-Acetylmuramyl-L-alanyl-D-isoglutamine hydrate (MDP), peroxidase conjugate 
goat anti-rabbit and anti-mouse and tetramethylammonium hydroxide (TMAH) 
solution 25% wt were obtained from Sigma Aldrich. Cell proliferation reagent 
WST-1 was obtained from Roche Applied Science (Madrid, Spain). LDH activity 
was measured by the Lactate Assay Kit II by BioVision. The human IL-1β ELISA 
Set II and skin milk powder were purchased from BD Biosciences. The 
caspase-1 (2225) and cleaved caspase-1 antibodies (4199) were purchased 
from Cell Signaling, while the α-tubulin antibody (#T8203) was obtained from 
Sigma-Aldrich. ECL Western blotting detection reagents were purchased from 
Amersham Pharmacia Biotech. Mouse IL-1β ELISA and TNF-α ELISA were 
purchased from R&D Systems (Minneapolis, MN, USA) Mouse IL-18 Platinum 
ELISA and Mouse IL-10 ELISA Ready-Set-Go were purchased from 
eBioscience. 
2.3. Synthesis of gated mesoporous silica nanoparticles  
2.3.1. Synthesis of MCM-41 mesoporous silica nanoparticles (MSNs).  
CTABr (1.00 g, 2.74 mmol) was dissolved in 480 mL of deionized H2O 
before adding a solution of NaOH (3.5 mL, 2.00 M). The solution temperature 
was adjusted to 80°C and then TEOS (5.00 mL, 2.57 × 10-2 mol) was added 
dropwise to the surfactant solution at maximum stirring. The mixture was stirred 
for 2 h to give a white precipitate. The solid was isolated by centrifugation and 
washed with deionized H2O until a neutral pH was obtained. Finally, the solid 
was dried at 60°C. To prepare the final porous material, MSNs were calcined at 
550°C in an oxidant atmosphere to remove the template phase. 
2.3.2. Synthesis of S1.  
In a typical synthesis, calcined MCM-41 nanoparticles (200 mg) and 
rhodamine B (76.64 mg, 0.16 mmol, 0.8 mmol/g solid) were suspended in 
CH3CN (7 mL). The suspension was stirred at room temperature for 24 h. Then 
an excess of (3 isocyanatopropyl)triethoxysilane (200 µl, 0.85 mmol, 4.25 
mmol/g solid) was added, and the final mixture was stirred at room temperature 
for 5.5 h. The resulting pink solid (S1) was finally isolated by centrifugation, 
washed twice with CH3CN (5 mL) and dried at 37°C. Taking into account the 
amount of rhodamine B used and the content in the loaded solid (see Table 2) a 
load efficiency of 54% was calculated. 
2.3.3. Synthesis of S1-P.  
First, S1 (200 mg) and ε-poly-L-lysine (200, mg, 1 mmol, 5 mmol of 
polymer/g solid) were dissolved in CH3CN (9 mL) and H2O (4 mL), followed by 
the addition of rhodamine B (50 mg) to avoid dye delivery from pores. 
Triethylamine (400 µl) was added and the final mixture was stirred for 2 h. 
Nanoparticles were centrifuged and washed thoroughly with water. The 
resulting solid S1-P was dried at 37ºC. 
2.3.4. Synthesis of S2.  
First calcined MSNs (1 g) and VX-765 (80, mg, 0.16 mmol, 0.16 mmol/g 
solid) were suspended in 10 mL of DMSO (VX-765 solubility in DSMO at 10 
mg/mL). The suspension was stirred at room temperature for 24 h to yield solid 
S2. Then excess (3 isocyanatopropyl)triethoxysilane (1 mL, 4.25 mmol, 4.25 
mmol/g solid) was added to a suspension that contained solid S2 (1 g) in 
CH3CN (25 mL).The final mixture was stirred at room temperature for 5.5 h and 
the resulting white solid (S2) was isolated by centrifuging, washed twice with 
CH3CN (5 mL) and dried at 37ºC. Taking into account the amount of VX-765 
used and the content in the loaded solid (see Table 2) a load efficiency of 81% 
was calculated. 
2.3.5. Synthesis of S2-P.  
First, S2 (1 g) and ε-poly-L-lysine (1 g, 5 mmol, 5 mmol of polymer/g solid) 
were dissolved in a mixture of CH3CN (50 mL) and H2O (30 mL). Triethylamine 
(1.6 mL) was added, and the final mixture was stirred for 5.5 h. Nanoparticles 
were centrifuged and washed thoroughly with water. The resulting solid S2-P 
was dried at 37ºC. 
2.4. Cargo release studies.  
To investigate the stimuli-responsive gating properties of the solid, 
rhodamine B and VX-765 delivery studies were performed in each case in water 
and in a highly competitive media (PBS buffer).  
In a first step, 2 mg of S1-P were placed in 1 mL of water at pH 8, and 
separated into two aliquots of 500 µl. Both samples were added to a volume of 
2.5 mL of water at pH 8 in the absence or presence of the pronase enzyme 
(0.12 mg/mL) from Streptomyces Griseus, respectively. Suspensions were 
stirred at 37ºC. At certain time aliquots were separated and centrifuged to 
eliminate the solid and dye delivery was monitored by the fluorescence 
emission band of rhodamine B at 575 nm (λex = 555 nm) in the aqueous phase. 
In a second step, studies in PBS were also performed. In this case, 2 mg of S1-
P were placed in 1 mL of PBS 1X at pH 7.5, and separated into two aliquots of 
500 µl. Both samples were added to a volume of 2.5 mL of PBS at pH 7.5 in the 
absence or presence of the pronase enzyme (0.12 mg/mL) from Streptomyces 
Griseus, respectively. In addition, experiments with denatured pronase (0.12 
mg/mL) were also performed to assess the role played by the enzyme in the 
gating mechanism of S1-P. Suspensions of S1-P in PBS were stirred at 37ºC. 
At certain time aliquots were separated and centrifuged to eliminate the solid 
and dye delivery was monitored by the fluorescence emission band of 
rhodamine B at 575 nm (λex = 555 nm) in the aqueous phase. 
In the S2-P delivery studies, 10 mg of the solid were suspended in 2 mL of 
water at pH 8. The suspension was separated into two aliquots and each was 
added to 4 mL of water at pH 8 in the absence or presence of the pronase 
enzyme (0.12 mg/mL) from Streptomyces Griseus, respectively. Suspensions 
were stirred at 37ºC. At certain time aliquots were separated and centrifuged to 
eliminate the solid. Drug delivery was monitored by analytical RP-HPLC with a 
UV detector using a mobile phase of CH3CN-H2O mixtures that contained 0.1% 
TFA at 1mL/min. Compound VX-765 was monitored at 220 nm.  
2.5. Cell culture conditions.  
THP-1 human leukemic monocyte cells were purchased from the German 
Resource Centre for Biological Materials (DSMZ) and were grown in RPMI-
1640 supplemented with 10% of FBS. Cells were incubated at 37ºC in an 
atmosphere of 5% carbon dioxide and 95% air, and underwent passage twice a 
week. For the experiments, THP-1 cells were seeded at 106 cell/mL in RPMI-
medium at 1% of FBS.  
2.6. Cytotoxicity cell assays.  
THP-1 cells were seeded in a 96-well plate and treated at different S1-P 
concentrations (0 (control), 25, 50, 100 and 150 µg/mL in PBS). Cells were 
incubated for 6 h and 24 h, and then viability was determined by a WST-1 assay 
and a lactate dehydrogenase (LDH) activity assay. For cell viability, WST-1 was 
added for 30 min and then absorbance was measured at 595 nm. The 
cytotoxicity of mesoporous silica nanoparticles against THP-1 was addressed 
by measuring the LDH activity in cell culture supernatants with the Lactate 
Assay Kit II following the manufacturer’s instructions. In this case cells were 
treated with 1% triton-X100, in the absence of nanoparticles, as a control 
positive of the LDH activity.  
2.7. Cellular uptake.  
In a first step, flow cytometry experiments were carried out to test the uptake of 
nanoparticles by THP-1 cells. For this purpose, cells were seeded in a 6 well-
plate and treated with S1-P at the 0 (control), 25 and 50 µg/mL concentrations 
(in PBS) for 30 min. Then cells were washed with PBS and quantification of 
rhodamine B fluorescence was performed by flow cytometry and analyzed using 
version 2.9 of the WinMDI program. To assess S1-P nanoparticle’s uptake by 
THP-1 cells, studied were carried out by confocal microscopy by means of 
rhodamine B associated fluorescence. THP-1 cells were seeded in a 6-well 
assay and treated with 50 µg/mL of nanoparticles and incubated at 37ºC for 1h. 
Then, cells were washed several times with PBS, and the fluorescence intensity 
was monitored using a Leica TCS SP2 confocal microscope. Two independent 
experiments that contained triplicates were performed.  
Finally, a solid containing covalently attached fluorescein was prepared and 
internalization studies were performed by flow cytometry and confocal 
microscopy as described above (see supporting information Fig.S2). 
 
2.8. VX-765 loaded nanoparticles activity cellular assays.  
Inhibition of inflammatory response by S2-P was studied in THP-1 human 
leukemic monocyte cells. For this purpose, cells were seeded in a 6-well plate 
and were then treated with S2-P at the 0 (control), 50, 75 and 100 µg/mL 
concentrations (in PBS). Free VX-765 was used as a reference at 1 and 2 µM 
(in DMSO) and with S2-P at 100 µg/mL as a nanoparticles control, respectively. 
After 30 min, NLPR-3 inflammasome was activated with lipopolysaccharide 
(LPS) from Escherichia coli (100 ng/mL) and muramyl dipeptide (MDP) (50 
µg/mL) stimulus, and was incubated for 6 h. Finally, the cell suspension was 
centrifuged and separated into the supernatant and pellet.  
The amount of IL-1β secreted in the cell culture supernatants of THP-1 
was measured by an enzyme-linked immunosorbent assay (ELISA) kit in 
accordance with the manufacturer’s instructions (Human IL-1β ELISA Set II 
from BD Biosciences). 
Western blot analyses were performed to detect the amount of active 
caspase-1 secreted into supernatants. Samples were concentrated by 
methanol/chloroform precipitation [51]. To determine the amount of pro-caspase 
1 as a control, whole cell extracts were obtained by lysing cells in a buffer that 
contained 25 mM Tris-HCl pH 7.4, 1 mM EDTA, 1 mM EGTA, and 1% SDS, 
plus protease and phosphatase inhibitors. Supernatants and lysates were 
resolved by SDS-PAGE, transferred to nitrocellulose membranes, blocked with 
5% non-fat milk, washed with 0.1% Tween/PBS and incubated overnight with a 
specific primary antibody against caspase 1 and cleaved caspase 1 (2225 C1 
and 4199 cleaved C1 from Cell Signalling). α-Tubulin was detected in cell 
lysates as the reference control. Membranes were washed and probed with the 
appropriate secondary antibody conjugated with horseradish peroxidase for 
enhanced chemiluminescence detection.  
2.9. Characterization of the ε-poly-L-lysine-capped nanoparticles activity 
in in vivo models of inflammation.  
All the studies were performed in accordance with European Union 
regulations for the handling and use of laboratory animals. Protocols were 
approved by the institutional Animal Care and Use Committee. Air pouches 
were produced by subcutaneous injections of 10 mL of sterile air into the back 
of male C57BL/6J mice (25-30 g). Three days later, 5 mL of sterile air were 
injected into the same cavity. Six days after the formation of air pouches, 
inflammation was induced by an injection of 1 mL of LPS (1µg/mL) into 
physiological saline [52-54].  
As a preliminary assay to test the activity of the solid, gated nanoparticles 
and free VX-765 were injected locally into the air pouch. Mice were treated with 
S2-P at 0.8 and 1.6 mg/kg or with the reference VX-765 at 0.008 mg/kg (in 0.5 
mL PBS + 0.1% DMSO). Air pouches in the control mice were treated with 
sterile physiological saline and 0.5 mL of PBS + 0.1% DMSO. Two hours after 
injecting LPS, mice were killed by cervical dislocation and the exudate in the 
pouch was collected with 1 mL of sterile physiological saline. After centrifuging 
exudates, supernatants were used to measure the amount of IL-1β, IL-18, IL-10 
and TNF-α by ELISA kit according to the manufacturer’s instructions. 
Then the same experiment was performed systemically by intravenous tail 
injection of nanoparticles and free drug. S2-P was injected at 75 mg/kg and VX-
765 at 10 mg/kg (in 0.150 mL PBS + 0.1% DMSO). Control mice were treated 
with 0.150 mL of vehicle. In this case supernatants were used to measure the 
amount of IL-1β and IL-18. One part of the exudate sample from the blank and 
the mice treated with LPS and S2-P was used to study the presence of silica 
nanoparticles at the inflammation focus.  
To determine the effect of targeting, presence of MSNs was determined by 
measuring the amount of silicon in the exudate from the air pouches by ICP-
MS, which obtained the exudate, as described above, of three groups of mice. 
A control group was treated with 0.150 mL of vehicle, a second group was 
treated with S2-P (75 mg/kg, intravenous) and a third group with the LPS 
stimulus (1 µg/mL, subcutaneous) and S2-P (75 mg/kg, intravenous).  Then 100 
µl of air pouch exudate were introduced into 15 mL of polytetrafluoroethylene 
(PTFE) tubes and 1 mL of TMAH 25% was added. The digestion temperature 
was set at 80°C and was kept for 2 h. After cooling digests were diluted to 10 
mL in polystyrene tubes. Finally 0.5 mL of the samples was diluted in a mixture 
of 10 mL of nitric acid 2% and hydrochloric acid 1%, and was measured in the 
7900 ICP-MS in H2 mode using germanium as an internal standard. 
3. Results and discussion 
3.1. Gated materials.  
As stated above, the combination of polymers and MSNs is an appealing 
approach to design gated nanocarriers for controlled release applications. In 
this context we used ε-poly-L-lysine as the capping system in MSNs as a 
suitable polymer anchored covalently to the silica surface in order to develop 
gated nanodevices capable of selectively releasing the cargo (rhodamine B or 
VX-765) in the presence of a target stimulus (pronase enzymes). A 
representation of the designed nanoparticles is provided in Scheme 1.  
 
Scheme 1. Representation of the prepared gated material capped with randomly 
attached ε-poly-L-lysine. 
 
MSNs were obtained following well-known procedures, loaded with the 
corresponding cargo and functionalized with 3-(triethoxysilyl)propyl isocyanate 
(solids S1 loaded with rhodamine B and S2 loaded with VX-765, see the 
Experimental Section). Another reaction with ε-poly-L-lysine allowed pores to be 
capped via the formation of urea bonds between the isocyanate groups in the 
nanoparticles and amine groups in the polymer (see Scheme 1) [55]. Following 
this simple procedure, solids S1-P and S2-P were obtained. 
 
3.2. Characterization of nanoparticles.  
The prepared solids were characterized by standard procedures. The 
powder X-ray patterns (PXRD) of the as-synthesized MCM-41, MCM-41 
calcined, S1, S1-P and S2-P nanoparticles are shown in Figure 1. The X-ray 
pattern of the as-synthesized MCM-41 solid presents the four mesoporous 
characteristic low-angle peaks of a hexagonal-ordered array, which can be 
indexed as (100), (110), (200) and (210) Bragg reflections. A significant shift of 
(100) reflection is observed in the MCM-41 calcined nanoparticles pattern, 
which corresponds to an approximate cell contraction of 4 Å induced by the 
condensation of silanol groups in the calcination step. In the PXRD pattern of 
solid S1-P and S2-P, a slight intensity reduction in the (100) reflection and loss 
of the (110) and (200) reflections (especially for S2-P) are observed, most likely 
due to the reduced contrast after the loading/functionalization process. 
Nevertheless, the permanence of the (100) reflection in the X-ray patterns 
strongly evidences that the mesoporous scaffold is maintained in the final gated 
nanoparticles.  
 
Fig. 1. Powder X-ray patterns of solids A) as-synthesized MCM-41 nanoparticles; B) 
MCM-41 calcined nanoparticles, C) S1 solid, D) S1-P solid and E) S2-P solid. TEM 
images of F) MCM-41 calcined nanoparticles, G) S1-P and H) solid S2-P showing the 
typical hexagonal porosity of the MCM-41 type mesoporous matrix. 
Furthermore, presence of the mesoporous structure was also confirmed by 
TEM analyses (Fig. 1, right). In the representative images, spherical 
nanoparticles were observed, with a mean diameter of 100 nm (92±9, 109±10 
and 103±7 nm for calcined MCM-41, S1-P and S2-P solids respectively) and 
the loaded and functionalized S1-P and S2-P solids maintained the initial 
morphology of the mesoporous silica starting matrix. The typical channels of 
mesoporous MCM-41 support were easily observed as either alternate black 
and white stripes or as a pseudo-hexagonal array of pores in the images.  
Dynamic light scattering (DLS) studies were also carried out. The results 
showed particles with a mean diameter of 90±15 nm for the starting calcined 
MCM-41 nanoparticles and of 122±16 and 114±8 for S1-P and S2-P, 
respectively (Fig. 2). The dynamic diameter of the functionalized nanoparticles 
was larger than that of the bare nanoparticles due to the presence of the 
capping ε-poly-L-lysine polymer.  
 
Fig. 2. Size distribution per number of particles obtained by the DLS studies for 
calcined MCM-41 nanoparticles, S1-P and S2-P. 
 
The N2 adsorption-desorption isotherm of the MCM-41 calcined 
nanoparticles is shown in Figure 3. The curve for the starting calcined 
nanoparticles displays an adsorption step with intermediate P/P0 values 
between 0.1 and 0.3, which correspond to a type IV isotherm that is typical of 
mesoporous MCM-41-type materials. This step can be related to nitrogen 
condensation that takes place inside mesopores by capillarity. The specific area 
was obtained by applying the BET model. From the BJH model on the 
adsorption curve of the isotherm (P/ P0 < 0.8), pore diameter and pore volume 
were calculated (Table 1). A second feature of the N2 adsorption-desorption 
isotherms of the MCM-41 calcined nanoparticles was the characteristic H1 
hysteresis loop that appeared on the curve at a high relative pressure (P/ P0 > 
0.8), which corresponded to the filling of the large pores between nanoparticles 
due to textural porosity. In this case, curves showed, in addition to the 
characteristic H1 hysteresis loop, a wide pore size distribution.  
For nanoparticles S1-P and S2-P (Fig. 3), the adsorption-desorption 
isotherms are typical of mesoporous systems with partially filled mesopores and 
the N2 volume adsorbed and the specific surface area significantly decrease 
compared with the starting MCM-41 material (see Table 1). 
 
Fig. 3. Nitrogen adsorption-desorption isotherm for: MCM-41 calcined mesoporous 
nanoparticles, S1-P, and S2-P solids. 
 
Table 1. BET specific surface values, pore volumes and pore sizes calculated from the 
N2 adsorption-desorption isotherms for selected materials. 
Solid SBET 
(m2  g-1 ) 
Pore volume 





1020 ± 28 0.63 2.2 
S1-P 413 ± 9 0.27 - 
S2-P 745 ± 40 0.20 - 
 
The contents of grafted molecules and cargoes in solids S1, S1-P, S2 and 
S2-P were determined by elemental and thermogravimetric analyses (see Table 
2). The isocyanatopropyl contents in solids S2 and S2-P (0.42 mmol/g SiO2) are 
nearly the same than those measured for S1 and S1-P solids (0.39 mmol/g 
SiO2) and subtle differences in contents could be ascribed to the different 
grafting and loading process used to prepare the solids (see Experimental 
section). In the case of the synthesis of S1 and S1-P the loading and the 
grafting processes were carried out in a one pot fashion using acetonitrile as 
solvent. On the other hand, solid S2 was loaded with VX-765 in DMSO and then 
isolated because the functionalization with isocyanatopropyl moieties was 
carried out in acetonitrile. The amount of polymer in both groups of materials is 
also quite similar (0.018 g/g SiO2 for S1-P and 0.014 g/g SiO2 for S2-P).  
 
Table 2. Content of molecular gate ε-poly-L-Lysine, the isocyanate group and the guest 
molecule in the different synthesized nanoparticles.  







g/ g SiO2 
S1 0.33 - 0.39 - 
S1-P 0.14 - 0.39 0.018 
S2 - 0.14 0.42 - 
S2-P - 0.14 0.42 0.014 
 
Finally, in order to assess the charge of the different prepared nanomaterials 
(calcined MCM-41, S1, S1-P, S2 and S2-P), the zeta potential were measured. 
As expected, calcined MCM-41 showed a zeta potential value of -29±1 mV due 
to the presence of silanolate moieties onto the external surface of the 
nanoparticles. The rhodamine B loaded solid had a positive value of zeta 
potential (21±1 mV) induced by the presence of the positively charged dye into 
the porous network of the nanoparticles. When the external surface of S1 was 
coated with poly-lysine (soild S1-P) the zeta potential increased to 35±4 mV due 
to the fact that biopolymer is positively charged at neutral pH. In the case of 
solid S2, a negative zeta potential was measured (-20±6 mV) probably due to 
the smaller quantity of VX-765 loaded inside the pores when compared to the 
rhodamine B presented in S1. Solid S2-P showed a positive zeta potential value 
(28±5 mV) due to the grafting of poly-lysine onto the external surface of the VX-
765-loaded nanoparticles. 
3.3. Cargo release studies.  
In a first step we tested the controlled release performances of S1-P 
nanoparticles in water (pH 8.0). In a typical experiment, 1 mg of solid was 
suspended in 1 mL of water at pH 8.0 in the absence and in the presence of 
pronase from Streptomyces griseous. Aliquots were taken at scheduled times, 
centrifuged to remove nanoparticles, and the cargo release was evaluated by 
measuring the emission band of rhodamine B at 575 nm (λex = 555 nm). The 
obtained results are shown in Fig. 4. A poor rhodamine B delivery occurred in 
the absence of the enzyme (less than 20%), which is indicative of remarkable 
pore closure (Fig. 4, curve B). Conversely in the presence of pronase pores 
opened due to the hydrolysis of the peptide bonds in the polymer with the 
subsequent dye delivery (Fig. 4, curve E). Nearly the same behavior was 
observed in a highly competitive media such as PBS. As expected, negligible 
rhodamine B release was observed in the absence of pronase (Fig. 4, curve A) 
whereas a marked dye delivery was observed when enzyme was present (Fig. 
4, curve D). Moreover, to assess the crucial role played by the enzyme in the 
release mechanism, cargo release for solid S1-P in the presence of denatured 
pronase was studied. As could be seen in curve C in Fig. 4 a negligible 
rhodamine B delivery was observed in the presence of denatured pronase. This 
result demonstrated the specific enzyme response of the gated nanoparticles. 
Besides, we analysed by HPLC the content of the aliquots obtained at 
scheduled times after solid S1-P was treated with pronase. HPLC 
measurements showed the presence of lysine in the aliquots, pointing toward a 
pronase-induced poly(lysine) hydrolysis as mechanism that governed 
rhodamine B release (see Supporting information).  
 
Fig. 4. Top: Enzyme-responsive rhodamine B release form solid S1-P: (A) in the 
absence of pronase in PBS at pH 7.5; (B) in the absence of pronase in water at pH 8.0;  
(C)  in the presence of denatured pronase in PBS at pH 7.5; (D) in the presence of 
pronase in PBS at pH 7.5; (E) in the presence of pronase in water at pH 8.0. Down: 
Enzyme-responsive VX-765 release from solid S2-P in water at pH 8.0 (F) in the 
absence and (G) in the presence of pronase.  
 
Similar release experiments were carried out with solid S2-P. In this case, 
delivery of VX-765 from nanoparticles was determined by HPLC analyses. A 
near-zero release was observed in the absence of pronase, whereas clear drug 
delivery was detected when enzymes were present (see Fig. 4, curves F and 
G). The VX-765 concentration reached (after 45 min of pronase addition) was 
ca. 700 nM, which is a value higher than the IC50 reported for this drug (ca. 100 
nM). This indicated that relevant therapeutic concentrations of VX-765 can be 
reached using solid S2-P. The delivery experiments also showed that after 1 h, 
the VX-765 concentration lowered in the medium (data not shown), which was 
most likely due to an enzyme-mediated hydrolysis or drug degradation. 
As it can also be observed in Fig. 4 an apparent faster payload release 
was observed for solid S2-P when compared with S1-P in the presence of 
enzyme and most likely ascribed to the fact that VX-765 is hydrolyzed by the 
enzyme used to trigger cargo release. This hydrolysis/degradation process of 
VX-765 avoids the detection of the real maximum delivery peak because after 1 
h the amount of payload release began to decrease (the hydrolysis of VX-765 
began to be faster than its release from S2-P). This is why maximum VX-765 
delivery appears at ca. 30 min. A second potential explanation that may also 
account for the different payload release observed for solids S1-P (loaded with 
rhodamine) and S2-P (loaded with VX-765) is, as noted above, the different 
physical properties of both molecules (such as solubility, polarity, etc). It is well 
known that delivery from silica mesoporous materials is highly influenced by the 
nature of the cargo. 
 
3.4. Characterization of ε-poly-L-lysine-capped nanoparticles activity in 
cellular models of inflammation.  
Cytotoxicity and cellular uptake studies with the dye-loaded S1-P 
nanoparticles in the THP-1 acute monocytic leukemia cell line were carried out 
as a preliminary step to further characterize S2-P nanoparticles in an in vivo 
anti-inflammatory model (vide infra). Cell viability studies that measured 
mitochondrial activity (WST-1 assays) in the presence of S1-P indicated that 
nanoparticles were well-tolerated by THP-1 cells at concentrations up to 150 
µg/mL (Fig. 5 A) after 6 and 24 h of exposure. Furthermore, a non significant 
LDH release, indicative of the absence of cellular necrosis or pyroptosis, was 
observed within the 25-150 µg/mL concentration range (see Fig. 5 B) both for 6 
and 24 h of treatments. 
To evaluate the cellular uptake of rhodamine B-loaded, ε-poly-L-lysine-
capped S1-P solid by THP-1 cells, internalization of nanoparticles was 
evaluated by flow cytometry and by confocal microscopy (Fig. 5 C and D). 
These studies demonstrated that up to 80% of the cellular population 
internalized S1-P 30 min upon treatment, which suggests that these 
nanoparticles can be used for delivery applications in THP-1 cells. Based on 
previous published results obtained with similar MSNs capped with enzyme 
degradable caps [39], it has been postulated that S1-P nanoparticles internalize 
by endocytosis. The resulting endosomal vesicles would fuse to lysosomes, 
where the activity of lysosomal enzymes would induce ε-poly-L-lysine hydrolysis 
and entrapped cargo delivery. 
 
Fig. 5. Cytotoxicity and internalization studies of S1-P at different concentrations of 
nanoparticles in THP-1 cells. A) Cell viability by the WST-1 assay, B) LDH-activity in 
the presence of nanoparticles. The positive control of LDH activity (P) was obtained by 
cellular lysis in 1%Triton-X100 (P) in the absence of nanoparticle. C) Percentage of 
fluorescent cells analyzed by flow cytometry in internalization studies D) S1-P uptake 
(in red) by THP-1 cells analyzed by confocal microscopy. Confocal images of cells 
treated with the S1-P nanoparticle at 50 µg/mL for 1 h. Data represent the mean±SEM 
of at least three independent experiments. 
3.5. Anti-inflammatory activity of S2-P nanoparticles and free VX-765 in a 
cellular model of inflammation.  
After performing internalization studies of S1-P nanoparticles in THP-1 
cells, further assays to test the anti-inflammatory activity of the S2-P 
nanoparticles in the same cell line were carried out. In a first step, it was verified 
that stimulation of THP-1 cells with LPS and MDP produced synthesis of pro-
IL1-β and activation of pro-caspase-1 by the inflammasome. Under these 
conditions, an increase in processed IL-1β and activated caspase-1 (casp-1 p20 
subunit) in the supernatant of cell cultures was observed (Fig. 6A and B, third 
line). Treatment of stimulated THP-1 with encapsulated VX-765 (S2-P 
nanoparticles) at the 50, 75 and 100 µg concentrations of solid/mL, or free VX-
765 (1 and 2 µM), diminished the release of both IL-1β and activated caspase-1 
to the medium (Fig. 6A and B, lines 5-7 and 8-9, respectively). Fig. 6 shows that 
the activity of S2-P nanoparticles at a concentration of 100 µg/mL is similar to 
that obtained using 1 µM of free VX-765. Moreover, the HPLC studies found 
that a concentration of 100 µg/mL of S2-P corresponded to an equivalent 
concentration of VX-765 of 13.7 µM (considering that all the encapsulated VX-
765 can be released). This indicated that for a similar drug concentration, 
nanoparticles were less effective than the free drug in assays using THP-1 
cells. However, these results strongly contrast with the in vivo studies carried 
out in a mouse model of inflammation in which nanoparticles S2-P displayed 
much more effective anti-inflammatory activity than the free drug (vide infra).    
 
Fig. 6. Inhibition of IL-1β and caspase-1 release induced by S2-P treatment in a 
cellular model of inflammation.  Quantification of inflammatory markers in the THP-1 
cells stimulated with LPS+MDP. A) IL-1β Levels from cell supernatants measured by 
enzyme-linked immunosorbent assay (ELISA). B) Levels of active caspase-1 (p-20) 
detected in the supernatants, inactive fraction of caspase 1 (p50) in cell lysates and, 
tubulin in cell lysates as a control by Western Blot. Data represent the mean±SEM of at 
least three independent experiments (* p< 0.005, ** p<0.0025, *** p<0.0001).  
 
3.6. Anti-inflammatory activity of S2-P nanoparticles and free VX-765 in 
the in vivo model of inflammation.  
Having demonstrated the activity of S2-P nanoparticles in cellular assays, 
we moved one step forward to characterize the anti-inflammatory properties of 
nanoparticles in an in vivo model of inflammation. 
In particular, firstly, S2-P activity was evaluated in a subcutaneous air 
pouch inflammation mouse model. In this model, injection of LPS into the air 
pouch induced an inflammatory response that was easily quantified by the 
increase in exudates of inflammatory mediators IL-1β, IL-18, TNF-α and IL-10. 
To confirm that in the air pouch in vivo model of inflammation, release of IL-1β 
is dependent of the inflammasome, we have demonstrated caspase-1 activation 
in the animal exudates by western blot analysis (see Supporting Information 
Fig. S2). After the intra-pouch administration of free VX-765 at 0.01 mg/kg or 
S2-P at 0.8 and 1.6 mg/kg (which corresponded to amounts of 0.05 and 0.1 
mg/kg of VX-765, respectively) in the mouse model, both inflammasome-
dependent interleukins IL-1β and IL-18 significantly reduced in exudates (Fig. 
7A and B). The therapeutic effect of VX-765 in all cases was the inhibition of ca. 
50% of inflammatory activity, and agreed with the cellular model results. In this 
case no significant differences in activity were found at similar concentrations of 
VX-765 free or encapsulated in S2-P. These results corroborated that treatment 
with VX-765-loaded mesoporous silica nanoparticles S2-P in an animal model 
was possible and that the inflammatory response properly reduced. In addition, 
levels of TNF-α and IL-10 were also analyzed as a control of inflammasome-
independent cytokines. As expected, no significant differences between the 
group treated only with LPS and the different treatments with the drug were 
observed (Fig. 7C and D). These data suggest that a reduction in the IL-1β and 
IL-18 levels resulted from the specific effect of VX-765 on caspase-1 activity.  
 
Fig. 7. In vivo inhibition of cytokines production by local administration of S2-P. Upon 
air pouch induction, the mice stimulated with LPS were treated with S2-P at 0.8 and 1.6 
mg/kg (which corresponded to 0.05 and 0.1 mg/kg of VX-765, respectively) or with VX-
765-free drug (0.01 mg/kg) for 2 h. Then presence of the cytokine in the air pouch 
exudates was analyzed by ELISA. Quantification of the assays (n=8) for IL-1β, IL-18, 
TNF-α and IL-10 is showed in A), B), C) and D) panels, respectively. Data represent 
the mean±SEM of at least three independent experiments (* p< 0.005, ** p<0.0025, *** 
p<0.0001). 
 
In another step, the activity of VX-765, either free or encapsulated (S2-P), 
was also analyzed in the same subcutaneous air pouch inflammation mouse 
model by an intravenous tail injection of VX-765 and S2-P. For the intravenous 
administration of VX-765, doses were adjusted according to previous reports 
[56]. As described above, the subcutaneous injection of LPS into the air pouch 
induced the secretion of IL-1β and IL-18 inflammatory cytokines in exudates. 
The treatment of LPS-stimulated mice with S2-P at 75 mg/kg i.v. (which 
corresponded to 4.2 mg/kg of VX-765) or free VX-765 at 10 mg/kg, which 
clearly reduced inflammatory cytokines levels in both cases. In this systemic 
approach, significant differences were also observed in the IL-1β and IL-18 
release upon treatment with nanoparticles. By taking advantage of drug 
protection and the preferential systemic distribution of nanoparticles to inflamed 
tissues, in this case the therapeutic effect of the encapsulated drug upon 
intravenous administration was noteworthily better than that of the free drug 
(Fig. 8). In particular, a significant reduction in LPS-induced inflammation (ca. 
50% of interleukins inhibition) was observed when S2-P was used, while 
differences were not significant for the free drug (around 20-25% of inhibition). 
Note that in these experiments the amount of loaded VX-765 in S2-P (4.2 
mg/kg) was lower than the dose of free drug administrated intravenously (10 
mg/kg), which indicated that, in this case, VX-765 was almost 4-fold more 
effective when encapsulated; i.e. the therapeutic effect clearly increased with 
nanoformulation. These results demonstrated the effectiveness of capped 
nanoparticles as passively targeted drug delivery systems to inhibit 
inflammatory response.  
 
Fig. 8. Anti-inflammatory effects of an intravenous administration of S2-P at 75 mg/kg 
(corresponds to 4.2 mg/kg of VX-765) in the air pouch inflammation model. IL-1β (A) 
and IL-18 (B) quantification from the exudates of the systemic assay in the air pouch 
mouse model in different mice groups (n=8). Data represent the mean±SEM of at least 
three independent experiments (* p< 0.005, ** p<0.0025, *** p<0.0001). 
 
Analyses of silica content in exudates (Fig. 9) confirmed our hypothesis. 
Similar background Si levels were detected in mice with no induced 
inflammation (not treated with LPS) in the exudate samples from the air pouch 
mouse when no nanoparticles or S2-P were intravenously injected (2.2 and 2.8 
µg of Si/ g exudate, respectively). Conversely in the S2-P-treated group (75 
mg/kg by intravenous injection), where inflammation was induced by LPS, a 
clear 2-fold increase in the Si concentration was observed in exudates (5.33 µg 
of Si/g exudate). These results suggested some specific targeting of 
nanoparticles at the inflammation focus. 
 
Fig. 9. Silica quantification in the exudate samples from the air pouch mouse. 
Quantification was performed in groups of mice not submitted to any nanoparticles 
treatment, S2-P treatment (without LPS) and from the air pouch mouse treated with 
LPS and S2-P by intravenous injection. 
 
4. Conclusions 
Our results demonstrate that delivery of anti-inflammatory drugs using 
gated mesoporous silica nanoparticles is a suitable tool to develop therapeutic 
strategies to treat inflammatory diseases. In particular, we developed a drug 
delivery system to inhibit the inflammatory response in an inflammatory model. 
The carrier consists in ε-poly-L-lysine-gated mesoporous silica nanoparticles 
capable of delivering the VX-765 drug in macrophages in in vitro and in vivo 
models of inflammation. Our design employs two basic concepts: (a) it is 
possible to take advantage of the passive targeting of nanoparticles to 
macrophages and (b) capped materials can deliver modulators of 
inflammasome in macrophages present at the inflammation focus. ε-poly-L-
lysine-functionalized nanoparticles are efficiently taken up by macrophage cells, 
most likely via endocytosis, and further reach autolysosomes where the polymer 
is degraded by lysosomal enzymes and cargo is released. We corroborate that 
using mesoporous silica nanoparticles in non toxic doses does not trigger an 
anti-inflammatory response in either macrophages or an in vivo air pouch 
mouse model. We prove that the nanoparticles which encapsulate VX-765 can 
be intravenously injected into the in vivo inflammation model and that the drug 
is able to reach the inflammation focus. The drug therapeutic effect is enhanced 
by a significant reduction in the inflammatory response when S2-P is injected, 
compared with the free drug in the animal model. In particular, VX-765 is ca. 4-
fold more effective when encapsulated. The demonstration that gated 
mesoporous silica materials can release drugs selectively at the inflammatory 
focus is state of the art and, as far as we know, no similar systems to those 
described herein to treat inflammatory-based diseases have been reported.  
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